Evidence map›Paper›PMID 29534721›Full record

Trial reportJournal of translational medicine2018

T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans.

Franklin R Toapanta, Paula J Bernal, Karen L Kotloff, Myron M Levine, Marcelo B Sztein

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01531530 (Safety, Clinical Tolerance, and Immunogenicity of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set, Live, Oral Shigella Flexneri 2a Vaccine Manufactured Using cGMP), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01531530 phase1completednot on this map

Safety, Clinical Tolerance, and Immunogenicity of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set, Live, Oral Shigella Flexneri 2a Vaccine Manufactured Using cGMP

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2011 to 2012Enrolled26ConditionsShigellaArmsCVD 1208S, a Shigella flexneri 2a live, oral vaccine, Placebo
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Toward aInternational journal of molecular sciences · 2023
    Review
  5. Further characterization ofFrontiers in immunology · 2023
    Article
  6. TheVaccines · 2022
    Review
  7. Recent Progress inPathogens (Basel, Switzerland) · 2021
    Review
  8. Glycoconjugate vaccines againstBiophysical reviews · 2021
    Review
  9. Review
  10. Infection and drug resistance · 2019
    Article
  11. Article
  12. A NovelmSphere · 2018
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Franklin R ToapantaDepartment of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. ftoapanta@som.umaryland.edu.ORCID 0000-0001-9439-0828
Paula J BernalDepartment of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Karen L KotloffDepartment of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Myron M LevineDepartment of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Marcelo B SzteinDepartment of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. msztein@som.umaryland.edu.
University of Maryland, Baltimore · US

Funding

Wild-type S. typhi Infection in Humans: Integrated Immunoprotective MechanismsU19AI082655 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FASANO, ALESSIO · 2009 to 2018
$27.8M
National Institute of Allergy and Infectious Diseases a component of the grant U19 AI082655National Institute of Allergy and Infectious Diseases U19 AI082655National Institute of Allergy and Infectious Diseases UM-CCHI Pilot ProjectNIAID NIH HHS U19 AI082655
6 · The paper itself

Abstract

backgroundShigellosis persists as a public health problem worldwide causing ~ 165,000 deaths every year, of which ~ 55,000 are in children less than 5 years of age. No vaccine against shigellosis is currently licensed. The live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S (S. flexneri 2a; ΔguaBA, Δset, Δsen) demonstrated to be safe and immunogenic in phase 1 and 2 clinical trials. Earlier reports focused on humoral immunity. However, Shigella is an intracellular pathogen and therefore, T cell mediated immunity (T-CMI) is also expected to play an important role. T-CMI responses after CVD 1208S immunization are the focus of the current study.

methodsConsenting volunteers were immunized orally (3 doses, 10

resultsFollowing the first immunization, T-CMI was detected in CD8 and CD4 T cells obtained from CVD 1208S recipients. Among CD8 T cells, the T effector memory (T

conclusionsCVD 1208S induces diverse T-CMI responses, which likely complement the humoral responses in protection from disease. Trial registration This study was approved by the Institutional Review Board and registered on ClinicalTrials.gov (identifier NCT01531530).

Indexed as

Immunity, CellularAdolescentAdultBacterial ProteinsCD8-Positive T-LymphocytesCytokinesFemaleHumansImmunologic MemoryKineticsLipopolysaccharidesMaleMiddle AgedNanoparticlesShigella flexneriShigella VaccinesBacterial ProteinsCytokinesLipopolysaccharidesShigella VaccinesVaccines, AttenuatedCVD 1208SIpaBNanoparticlesOral vaccineShigella flexneri 2aT cell mediated immunity

Identifiers

PMID29534721
PMCPMC5851169
OpenAlexW2802663190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.